The Endpoints 11: biopharma’s most promising startups in 2026
True innovation has never been harder to see. New financial models are changing how and where new drugs get developed. Promising molecules draw a dozen copycats right out the gate. The genuinely risky, boundary-pushing work often happens behind closed doors. Endpoints editors sifted through the muddle to uncover eleven companies whose work clears the bar....
